REVELATION BIOSCIENCES, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$9.1M | -$8.0M | -$8.7M | -$10.9M | -$12.0M |
| Operating expenses | $9.1M | $8.0M | $8.7M | $10.9M | $12.0M |
| Cash from operations | -$8.3M | -$18.3M | -$7.3M | -$11.2M | -$11.1M |
| Capital expenditure | — | $19,171 | — | — | $131,963 |
| Free cash flow | — | -$18.3M | — | — | -$11.2M |
| Share repurchases | — | — | — | — | $35.5M |
| Total assets | $11.6M | $6.6M | $12.2M | $5.5M | $2.0M |
| Total liabilities | $2.7M | $1.9M | $5.6M | $4.5M | $2.1M |
Shares outstanding 3.9M · Free float 35.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.